• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Neurology

CXCL13 shows potential as anti-NMDA receptor encephalitis biomarker

byAshley AaroeandJames Jiang
December 2, 2014
in Neurology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Anti-N-methyl-D-aspartate receptor (Anti-NMDAR) encephalitis is an autoimmune disorder, which can result in behavior changes, psychosis, executive dysfunction, seizures, and catatonia.

2. C-X-C motif chemokine 13 (CXCL13) is a substance that attracts B-cells, and was found to be elevated in the majority of patients with anti-NMDAR encephalitis. It may be useful as a biomarker for treatment response.

Evidence Rating Level: 2 (Good)

Study Rundown: Anti-NMDAR encephalitis is a disorder that stems from autoimmune attack on predominately the NR1 subunit of the N-methyl-D-aspartate receptor found in many neurons. It is most common in children, young adults, and women (the latter due to an association with ovarian teratomas). It can cause a multitude of symptoms, including psychosis, behavior changes, catatonia, seizures, and movement disorders. This study hypothesized that C-X-C motif chemokine 13 (CXCL13), a B-cell chemokine that may be associated with other autoimmune diseases such as multiple sclerosis and neuromyelitis optica, would be elevated in the cerebrospinal fluid of anti-NMDAR encephalitis patients.

The authors measured serum and CSF CXCL13 in patients with anti-NMDAR encephalitis, negative controls and positive controls. They found that in the early stages of disease, 70% of patients studied had elevated CSF CXCL13. The CSF concentration of CXCL13 appeared to correlate with poor response to therapy, presence of prodromal symptoms, and intrathecal synthesis of NMDAR antibodies. A secondary increase of CXCL13 was seen in the CSF of patients who had relapsing symptoms. These findings suggest that CXCL13 has clinical utility as a biomarker in this disease to detect relapse and assess response to treatment. The presence of both positive and negative control groups is a strength of this study, as is the correlation with intrathecal NMDAR-antibodies.

Click to read the study, published today in JAMA Neurology

RELATED REPORTS

The Scan by 2 Minute Medicine®: Billy Joel’s Brain Condition, Gigi Robinson’s Surgical Advocacy, Climate and Cancer Risk, and West Nile Virus Reaches the United Kingdom

Risk of Encephalitis and Meningitis after COVID-19 Vaccination in South Korea

The 2 Minute Medicine Podcast Episode 5

Relevant Reading: CXCL13 is a Biomarker of Inflammation in Multiple Sclerosis, Neuromyelitis Optica, and Other Neurological Conditions

In-Depth [retrospective cohort]: This study was conducted at the University of Pennsylvania and the University of Barcelona. Cerebrospinal fluid and serum samples were examined from a total of 167 patients seen from 2008 to 2013. Inclusion criteria included an adequate number of samples per patient for study and 8 month follow-up. Twenty-five randomly selected patients with non-inflammatory neurologic conditions, such as primary psychiatric disease, epilepsy, headache disorders, and intracranial hypertension served as the negative controls for this study, and 9 patients with neuroborreliosis, which also presents with high CSF CXCL13, served as positive controls. Serum and CSF CXCL13 levels were determined by enzyme-linked immunosorbent assay (ELISA). The modified Rankin scale (mRS) was used to assess symptom burden and track clinical course.

The mean CSF CXCL13 concentration in patients with NMDAR encephalitis was 9.6 pg/mL (95%CI 7.2-12.9), compared to the negative control group at 1.4 pg/mL (95% CI 1.1-1.9). There was no significant difference in serum CXCL13 concentration between anti-NMDAR encephalitis patients and the negative control group (53.1 pg/mL vs 55.2 pg/mL with overlapping confidence intervals). About 70% of patients with early-stage anti-NMDAR encephalitis had increased CSF CXCL13 relative to controls (p<0.001). High CSF CXCL13 was associated with limited response to therapy, intrathecal NMDAR-antibody synthesis, and clinical relapse. Ten of 15 patients with limited treatment response and no relapses were found to have high CSF CXCL13 concentrations, compared with no such elevations in the group of 13 patients who had a favorable response to treatment.

More from this author: Increased orexin levels linked with poor sleep quality in Alzheimer Disease, Antibiotic prescription patterns in China may contribute to resistance, Glatiramer acetate (Copaxone) therapy may alter B cell function in multiple sclerosis

Image: PD

©2014 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. No article should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2 Minute Medicine, Inc.

Tags: biomarkerEncephalitis
Previous Post

2 Minute Medicine Rewind November 23 – November 30, 2014

Next Post

Socioeconomically disadvantaged neighborhoods linked to increased rehospitalization rates

RelatedReports

The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Billy Joel’s Brain Condition, Gigi Robinson’s Surgical Advocacy, Climate and Cancer Risk, and West Nile Virus Reaches the United Kingdom

May 27, 2025
Medical vaccine exemptions increase after elimination of nonmedical exemptions
Infectious Disease

Risk of Encephalitis and Meningitis after COVID-19 Vaccination in South Korea

March 22, 2024
2MM Podcast

The 2 Minute Medicine Podcast Episode 5

February 9, 2023
Cardiology

Ziltivekimab antagonism of IL-6 reduces inflammation and thrombosis in patients with atherosclerotic risk factors

June 10, 2021
Next Post
Socioeconomically disadvantaged neighborhoods linked to increased rehospitalization rates

Socioeconomically disadvantaged neighborhoods linked to increased rehospitalization rates

Tumor-specific mutant antigens are potential targets for cancer therapy [PreClinical]

Tumor-specific mutant antigens are potential targets for cancer therapy [PreClinical]

Multiple factors may increase risk of falls in young children

Multiple factors may increase risk of falls in young children

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Cerebral embolic protection does not decrease stroke incidence in TAVI patients
  • Nerandomilast slows FVC decline in progressive pulmonary fibrosis
  • 2 Minute Medicine: Pharma Roundup – Gastric Immunotherapy Gains, Prostate Pill Expansion, Five-Minute Myeloma Dosing, and Streamlined CAR-T Access [July 8th 2025]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.